Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan

/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...

Related Keywords

United States ,Boston ,Massachusetts ,Japan ,China ,Kohei Shitara ,Valerie Malyvanh Jansen ,National Cancer Center Hospital ,Department Of Gastrointestinal Oncology ,Prnewswire Elevation Oncology Inc ,Corporate Communications Investor Relations ,Nasdaq ,Elevation Oncology Inc ,Exchange Commission ,Chief Medical Officer ,Gastrointestinal Oncology ,National Cancer Center Hospital East ,Elevation Oncology ,Private Securities Litigation Reform Act ,Oncology Investor ,Corporate Communications ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,